Claroid Pharmaceuticals Limited

rhp filedRefreshing

Source: SEBI

DRHP30 Sept 2026completed
RHP7 Oct 2026completed
Price band—not yet reached
Opens—not yet reached
Closes—not yet reached
Allotment—not yet reached
Listing—not yet reached

Issue price

—

Issue size

—

Fresh issue

—

Offer for sale

—

Restated financials

As stated in the prospectus. Standalone vs consolidated is kept as filed.

Fiscal 2026

₹ in Lakhs

Revenue: 16,971.53
EBITDA: 4,093.64
EBITDA margin: 24.12%
PAT: 2,270.44
EPS (basic): 5.41
Net worth: 4,437.58
Total debt: 1,426.43
Cash from operations: 1,701.69
RoE: 68.73%

Fiscal 2025

₹ in Lakhs

Revenue: 9,969.94
EBITDA: 1,435.25
EBITDA margin: 14.40%
PAT: 721.53
EPS (basic): 1.72
Net worth: 2,169.18
Total debt: 2,513.64
Cash from operations: 1,517.48
RoE: 39.90%

Fiscal 2024

₹ in Lakhs

Revenue: 6,299.84
EBITDA: 1,177.49
EBITDA margin: 18.69%
PAT: 411.73
EPS (basic): 2.88
Net worth: 1,447.48
Total debt: 1,830.62
Cash from operations: (251.30)
RoE: 72.53%

Context

Financial trajectory

The company has demonstrated a strong financial trajectory with increasing revenues and profits over the past three fiscal years. However, it has also faced challenges with negative cash flows in certain periods, indicating potential volatility in financial performance.

Cash-flow quality

The company reported positive cash flow from operating activities in Fiscal 2026, but previous years showed negative cash flows, raising concerns about the sustainability of cash generation.